A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy

Registry ID

EUCTR2010-024017-31

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

NOVARTIS FARMA

Start date

2011-03-15

Last update

2026-08-16

Conditions

• Relapsing Remitting Multiple Sclerosis

Summary

The primary objective of the study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).

Locations

• , , Italy

Related clinical trials

• A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
• Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

View on source registry